Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05787249 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts

StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results posted: Oct 2, 2026 Primary endpoint revised · Eligibility criteria expanded, about 10 words · Secondary endpoints revised (5) · 1 more Show 4 more changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints revised (5)
    • Publications: details revised at 14 of 14 entries
  2. Start date: Sep 18, 2023 to Oct 4, 2023v13
  3. Trial status: Active, Not Recruiting to Completed Enrollment target: estimated 1600 to confirmed 1358 · Primary and study completion dates changed from estimate of Apr 2025 to Apr 4, 2025v12 Show 2 more changesShow less
    • Enrollment target: estimated 1600 to confirmed 1358
    • Primary and study completion dates changed from estimate of Apr 2025 to Apr 4, 2025
  4. Start date: Oct 4, 2023 to Sep 18, 2023v11
  5. Trial status: Enrolling by Invitation to Active, Not Recruiting Primary completion date: Oct 2024 to Apr 2025 · Collaborators expanded, about 4 wordsv10 Show 2 more changesShow less
    • Primary completion date: Oct 2024 to Apr 2025
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Sep 2024 to Oct 2024 Completion date: Sep 2024 to Apr 2025v9 Show 1 more changeShow less
    • Completion date: Sep 2024 to Apr 2025
  2. Lead sponsor: University of Pennsylvania to Abramson Cancer Center at Penn Medicinev8
  3. Re-verified, no change to tracked fieldsv7
  4. Start date: Sep 27, 2023 to Oct 4, 2023v6
  5. Start date: Sep 5, 2023 to Sep 27, 2023v5
  6. Start date: Apr 10, 2023 to Sep 5, 2023 Primary endpoints: 2 to 1 · Enrollment target: 2000 to 1600 · Primary and study completion dates: Apr 2024 to Sep 2024 · 3 morev4 Show 6 more changesShow less
    • Primary endpoints: 2 to 1
    • Enrollment target: 2000 to 1600
    • Primary and study completion dates: Apr 2024 to Sep 2024
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: 2 to 5
    • Study description shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  7. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 1 · Start date changed from estimate of Mar 2023 to Apr 10, 2023v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2023 to Apr 10, 2023
  8. Primary endpoints revised (2)v2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this group, and whether this effect differs between Black and White women.
Trial Details
NCT Number NCT05787249
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 1,358 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov